RS-2024-00337392

Development of Innovative Gene Therapy Candidate for Hepatocellular Carcinoma Targeting High-Risk Dual-Specific Protein Phosphatase

CUROGEN Technology

CUROGEN

ONCOLOGY | **Lead**

Product Type	[Gene therapy] CR-G001; AAV8 expressing CR-P1 under the control of hepatocyte selective TBG promoter
Indication	Hepatocellular Carcinoma (MASH-associated and HBV-positive HCC)
Target	CR-P1 (Code name)
MoA(Mechanism of Action)	• Inactivation of hepatocellular carcinoma cells - Recovery from hepatocyte damage - Inhibition of hepatic oncogenic cell cycle • Improvement of anti-tumor immunity - Improvement of anti-tumor activity of macrophage - Improvement of $CD8^+$ T cell cytotoxic & effector function
Competitiveness	• First-in-class HCC gene therapy • Excellent treatment efficacy with single injection in various HCC murine models • Better therapeutic interventions compared to mtTKIs and ICIs • Substantial improvement of modality with combined (mtTKI and ICI) treatments
Development Stage	Lead
Route of Administration	Portal vein or hepatic artery injection

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund